You just read:

BioSight Will Present Interim Results From a Phase 1/2 Clinical Trial of Astarabine for Treating Acute Leukemia at the ASH Annual Meeting 2015

News provided by

BioSight Ltd.

Oct 26, 2015, 08:00 ET